Alaunos Therapeutics (TCRT)
(Delayed Data from NSDQ)
$1.15 USD
+0.07 (6.48%)
Updated May 24, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Alaunos Therapeutics, Inc. [TCRT]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Alaunos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alaunos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TCR-T Program Terminated; Reviewing Strategic Options; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Alaunos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Catalysts in 2023; Upgrade to Buy With a $1.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Alaunos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IND Amendments Could Speed up TCR-T Library Study; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Alaunos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Initial Readout From TCR-T Library; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Alaunos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Update From TCR-T Library Study; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Alaunos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TCR-T Library Study Initiated; ASGCT Update on mbIL-15 TCR-T; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Alaunos Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TCR-T Library Study Initiated; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
|